EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Arich Enterprise Co Ltd (4173) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Arich Enterprise Co Ltd TWD 24.44, price TWD 17.10, upside +42.9%, quality 51 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · TW · ISIN TW0004173000

AE Thin data Sep 24, 2026

Arich Enterprise Co Ltd

4173 · TWO

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value 24.44 TWD · Undervalued (+43%)
!Quality 51/100
!Expensive Growth (revenue 5y +4.3 %/yr)
!Thin margins · 4.9% net margin (TTM)
!Low debt · negative free cash flow
·6.08% dividend yield
✓Ranks above peers (9/13)
!Narrow moat 31/100
!Evidence only low, so the estimate is less certain
!Weak on future: 23 out of 100
!Weak on past: 16 out of 100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

27.40 TWD 15.58 TWD Fair Value 24.44 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 15.58 TWD – 27.40 TWD · fair‑value band 18.33 TWD – 30.55 TWD · the 17.10 TWD price screens below the 24.44 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Arich Enterprise Co in your weekly email

Every Wednesday you see whether Arich Enterprise Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Arich Enterprise Co., Ltd. engages in the marketing, promotion, and distribution of pharmaceuticals in Taiwan. It offers sales promotion for pharmaceutical products; warehousing and logistics, and processing services.

Show more

Arich Enterprise Co., Ltd. engages in the marketing, promotion, and distribution of pharmaceuticals in Taiwan. It offers sales promotion for pharmaceutical products; warehousing and logistics, and processing services. The company provides distribution and logistics services, including assists manufacturers with bidding processes; inventory management, order processing, invoicing, goods delivery, collection, customer complaint handling, and provides integrated pharmaceutical distribution services. In addition, it offers activities, such as hospital tender and bidding; pharmaceutical pricing negotiations; cold chain, clinical trial drug, and controlled drugs management; information, and financial flow. Arich Enterprise Co., Ltd. was founded in 1969 and is based in New Taipei City, Taiwan.

Stock analysis

Arich Enterprise Co Ltd (4173) currently trades at 17.10 TWD, while our model-based Fair Value estimate is 24.44 TWD, implying the stock looks roughly 30.0% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of 47.46 TWD per share, and 13 of the 15 models we run sit above the 17.10 TWD price.

Bear case: the Earnings-Based group reads lowest at 10.29 TWD, and 2 of the 15 models stay below the price. Evidence for this calculation is low.

Scenario range: 18.33 TWD (bear) to 30.55 TWD (bull), the price of 17.10 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Arich Enterprise Co Ltd reported revenue of 1.5B TWD in FY2025 versus 946M TWD in FY2021, a compound +13.1%/yr. Reported net income was 86.8M TWD in FY2025, compounding +11.9%/yr from FY2021.

Key figures

Market cap 1.3B TWD (≈ $40.1M) · P/E ratio 14.7 · P/S ratio 0.83 · EPS (TTM) 1.16 TWD · Dividend yield 6.1% · Net margin 5.6% · Return on equity 4.1% · Return on assets (EBIT) 1.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 43%, 4173 screens cheaper than that median.

Fair Value models

Bear 18.33 TWD Fair Value 24.44 TWD Bull 30.55 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0881 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings 32.89 TWD 47.46 TWD 70.06 TWD 76
Residual Income 19.96 TWD 19.78 TWD 17.80 TWD 76
EPV 19.84 TWD 21.47 TWD 22.88 TWD 74
All 15 models by family
DCF Models
Owner Earnings 32.89 TWD 47.46 TWD 70.06 TWD 76
Earnings-Based
Graham-Dodd 7.91 TWD 29.79 TWD 40.31 TWD 64
Lynch FV 7.20 TWD 10.29 TWD 13.37 TWD 61
PEG = 1.0 7.20 TWD 10.29 TWD 13.37 TWD 57
EPV 19.84 TWD 21.47 TWD 22.88 TWD 74
Multiples
P/E Multiple 18.33 TWD 24.44 TWD 30.55 TWD 63
P/S Multiple 14.84 TWD 19.79 TWD 24.73 TWD 58
P/B Multiple 14.84 TWD 19.79 TWD 24.73 TWD 55
EV/EBIT 27.24 TWD 33.14 TWD 39.04 TWD 66
EV/EBITDA 31.89 TWD 39.34 TWD 46.79 TWD 67
EV/Revenue 22.17 TWD 27.58 TWD 33.00 TWD 54
Asset-Based
NCAV (Graham) 13.49 TWD 18.07 TWD 26.97 TWD 54
Economic Profit
Residual Income 19.96 TWD 19.78 TWD 17.80 TWD 76
ROIC Compounder 19.84 TWD 21.47 TWD 22.88 TWD 72
Growth Earnings
Growth-Adj P/E 13.24 TWD 18.91 TWD 24.59 TWD 67

Open the full fair value analysis →

Notify me when 4173 reaches fair value

Put 4173 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 47 · Market factors (momentum, volatility) 38

Profitability 22
Margins and returns on capital today
Quality Growth 68
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 57
Balance sheet, leverage, solvency risk
Investment 93
Disciplined investing over empire-building
Low Volatility 99
Calm price path (market factor)
Momentum 20
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+19.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+15.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.5%
Dividend (yield on the price)6.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 7%
⚠ Revenue per share shrinking 5.5%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Watch 4173, get fair value alerts →

Compare Arich Enterprise Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 61 stocks

Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 51 · Below median
Fair Value upside +43% · Above median
Profitability
Return on equity (TTM) 4% · Below median
Return on assets 1% · Below median
Net margin (TTM) 5% · Top 25%
Operating margin (TTM) 6% · Top 25%
Growth and dividend
Revenue growth 5% · Above median
Dividend yield (TTM) 6.1% · Top 25%

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 14.7× · Cheapest 25%
P/B 0.63× · Cheapest 25%
P/S (TTM) 0.82× · Pricier than median
EV/EBITDA 5.5× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)91 · sector 33
FUTURE (revenue growth)23 · sector 19
PAST (return on equity)16 · sector 22
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)100 · sector 64

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Alibaba Health Information Technology Limited 0241 HK$2.84 HK$2.03 −28%
Yifeng Pharmacy Chain Co 603939 ¥22.09 ¥40.59 +84%
DaShenLin Pharmaceutical Group 603233 ¥17.97 ¥26.45 +47%
LBX Pharmacy Chain Joint Stock Company 603883 ¥12.90 ¥14.19 +10%
MedPlus Health Services Limited MEDPLUS ₹662.00 ₹393.38 −41%
Yixintang Pharmaceutical Group 002727 ¥10.96 ¥9.51 −13%
Anhui Huaren Health Pharmaceutical Co 301408 ¥15.56 ¥17.12 +10%
ShuYu Civilian Pharmacy Corp 301017 ¥12.95 ¥5.91 −54%
Apotea AB APOTEA kr 81.90 kr 46.46 −43%
Luyan Pharma Co 002788 ¥11.24 ¥15.91 +42%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Arich Enterprise Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4173

Frequently asked questions

Is Arich Enterprise Co Ltd (4173) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 24.44 TWD versus a price of 17.10 TWD, about +43% upside (undervalued).
What is the fair value of 4173?
Our model-based fair value for Arich Enterprise Co Ltd is 24.44 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 17.10 TWD.
What is the quality score of 4173?
Arich Enterprise Co Ltd has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Arich Enterprise Co Ltd (4173)?
Our model-based price target is the fair value of 24.44 TWD (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 18.33 TWD, optimistic scenario 30.55 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Arich Enterprise Co Ltd stock forecast for 2026?
Our models put fair value at 24.44 TWD, about +43% upside versus a price of 17.10 TWD (undervalued). Cautious scenario 18.33 TWD, optimistic scenario 30.55 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Arich Enterprise Co Ltd (4173)?
Arich Enterprise Co Ltd reported trailing-twelve-month revenue of about 1.6B TWD (latest available figure, as of Sep 24, 2026).
Does Arich Enterprise Co Ltd pay a dividend?
Arich Enterprise Co Ltd currently shows a dividend yield of about 6.08% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Arich Enterprise Co Ltd (4173)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Arich Enterprise Co Ltd it is 24.44 TWD per share (as of Sep 24, 2026), against a price of 17.10 TWD. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Arich Enterprise Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4173 trades below its calculated fair value: price 17.10 TWD, fair value 24.44 TWD, a gap of about +43% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4173?
No. The price is what the market pays today (17.10 TWD); the fair value is what the company's own numbers justify (24.44 TWD). For Arich Enterprise Co Ltd the two are 7.34 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Arich Enterprise Co Ltd worth?
The market values Arich Enterprise Co Ltd at about 1.3B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 17.10 TWD; our models calculate a fair value of 24.44 TWD per share.
What do the bullish and bearish scenarios say about 4173?
Our models span a range for Arich Enterprise Co Ltd: cautious scenario 18.33 TWD, base 24.44 TWD, optimistic 30.55 TWD per share (as of Sep 24, 2026, price 17.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4173?
Arich Enterprise Co Ltd trades at a price-to-earnings ratio of 14.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 24.44 TWD is built from several models across several years. Other multiples: P/B 0.6, P/S 0.8, EV/EBITDA 5.5.
How solid is the balance sheet of Arich Enterprise Co Ltd (4173)?
Balance-sheet figures for Arich Enterprise Co Ltd (as of Sep 24, 2026): return on equity 4.1%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 4173 from its 52-week high?
Arich Enterprise Co Ltd trades at 17.10 TWD, about 33% below its 52-week high of 25.35 TWD and 1% above the low of 17.00 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 24.44 TWD is for.
Which stocks are comparable to Arich Enterprise Co Ltd?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Arich Enterprise Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 17.10 TWD, calculated fair value 24.44 TWD (+43%), Quality Score 51/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4173 calculated?
We run Arich Enterprise Co Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 24.44 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Arich Enterprise Co Ltd currently trades 43 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Arich Enterprise Co Ltd (4173)?
The closing price on Sep 24, 2026 was 17.10 TWD. Our model-based fair value is 24.44 TWD, about +43% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Arich Enterprise Co Ltd right now?
The price is below even our cautious bear case (18.33 TWD). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of Arich Enterprise Co Ltd

How large is the market capitalisation of Arich Enterprise Co Ltd (4173)?
The market capitalisation of Arich Enterprise Co Ltd is 1.3B TWD (≈ $40.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Arich Enterprise Co Ltd (4173)?
The price-to-sales ratio of Arich Enterprise Co Ltd is 0.83 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Arich Enterprise Co Ltd (4173)?
Earnings per share at Arich Enterprise Co Ltd are 1.16 TWD (price ÷ EPS = P/E 14.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Arich Enterprise Co Ltd (4173)?
The dividend yield of Arich Enterprise Co Ltd is 6.1% (payout 89.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Arich Enterprise Co Ltd (4173)?
The net margin of Arich Enterprise Co Ltd is 5.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Arich Enterprise Co Ltd (4173)?
The return on equity (ROE) of Arich Enterprise Co Ltd is 4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Arich Enterprise Co Ltd (4173)?
On an EBIT basis the return on assets of Arich Enterprise Co Ltd is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Arich Enterprise Co Ltd (4173)?
The operating margin of Arich Enterprise Co Ltd is 5.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Arich Enterprise Co Ltd (4173)?
Revenue at Arich Enterprise Co Ltd is growing +4.5% versus a year earlier (3y avg +15.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Arich Enterprise Co Ltd (4173)?
Earnings per share at Arich Enterprise Co Ltd are growing −32.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Arich Enterprise Co Ltd (4173) generate?
The free cash flow of Arich Enterprise Co Ltd is −1.9B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Arich Enterprise Co Ltd (4173) hold?
Arich Enterprise Co Ltd holds more cash than debt, 225M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Arich Enterprise Co Ltd in the live analysis

One click puts Arich Enterprise Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.